The Manufacturers Life Insurance Company bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 42,298 shares of the company's stock, valued at approximately $1,037,000. The Manufacturers Life Insurance Company owned about 3.50% of Oruka Therapeutics at the end of the most recent reporting period.
Wall Street Analysts Forecast Growth
ORKA has been the subject of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Monday, November 25th. Stifel Nicolaus began coverage on Oruka Therapeutics in a report on Friday, October 11th. They issued a "buy" rating and a $49.00 target price for the company. Wedbush restated an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research note on Friday, September 13th. They issued a "buy" rating and a $40.00 price objective for the company. Finally, TD Cowen initiated coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set a "buy" rating on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $43.17.
View Our Latest Research Report on ORKA
Oruka Therapeutics Stock Up 2.9 %
Shares of NASDAQ ORKA traded up $0.62 during midday trading on Friday, hitting $21.94. 250,343 shares of the stock traded hands, compared to its average volume of 73,350. Oruka Therapeutics, Inc. has a one year low of $18.20 and a one year high of $53.88. The company's 50 day moving average is $25.16.
Oruka Therapeutics Profile
(
Free Report)
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
See Also
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
